<DOC>
	<DOCNO>NCT02172755</DOCNO>
	<brief_summary>The purpose study determine effect age pharmacokinetic profile BIA 2-093 active metabolite .</brief_summary>
	<brief_title>Single-dose Steady-state Pharmacokinetics BIA 2-093 Its Metabolites</brief_title>
	<detailed_description>This single-centre , open-label , parallel group , non-randomised study single-dose phase ( Phase A ) follow multiple-dose phase ( Phase B ) , 12 healthy elderly 12 healthy young subject . During whole study , subject receive single 600 mg dose BIA 2-093 ( Phase A ) follow 600 mg BIA 2-093 daily 8 day Phase B . Phase B begin 96 hour post-Phase A dose .</detailed_description>
	<mesh_term>Eslicarbazepine acetate</mesh_term>
	<criteria>Male female subject age 18 40 year , inclusive OR male female subject age 65 year . If young , subject within 15 % ideal body weight OR , elderly , subject within 20 % ideal body weight accord Metropolitan Life Insurance Table . Subjects healthy determine prestudy medical history , physical examination , neurological examination , 12lead ECG . Subjects clinical laboratory test acceptable Investigator . Subjects negative HBsAg , HCVAb HIV1 HIV2 Ab test screen . Subjects negative alcohol drug abuse screen . Subjects nonsmoker smoke less 10 cigarette equivalent per day . Subjects able willing give write informed consent . ( If female ) She childbearing potential reason surgery menopause , childbearing potential , use one follow method contraception : double barrier intrauterine . ( If female less 40 year old ) She negative pregnancy test screening . Subjects conform inclusion criterion . Subjects clinically relevant history presence respiratory , gastrointestinal , renal , hepatic , haematological , lymphatic , neurological , cardiovascular , psychiatric , musculoskeletal , genitourinary , immunological , dermatological , connective tissue diseases disorder . Subjects clinically relevant surgical history . Subjects clinically relevant family history . Subjects history relevant atopy . Subjects history relevant drug hypersensitivity . Subjects history alcoholism drug abuse . Subjects consume 14 unit alcohol week . Subjects significant infection know inflammatory process screen and/or admission . Subjects acute gastrointestinal symptom time screen and/or admission ( e.g. , nausea , vomit , diarrhoea , heartburn ) . Subjects use drug within 2 week first dose . Subjects use investigational drug and/or participate clinical trial within 3 month first admission study . Subjects previously receive BIA 2093 . Subjects donate and/or receive blood blood product within previous 2 month prior screen . Subjects vegetarian , vegan and/or medical dietary restriction . Subjects could communicate reliably investigator . Subjects unlikely cooperate requirement study . Subjects unwilling unable give write informed consent . ( If female ) She pregnant breastfeeding ( If female ) She childbearing potential use authorise effective contraceptive method .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Eslicarbazepine acetate</keyword>
	<keyword>BIA 2-093</keyword>
</DOC>